Biotium Introduces New Line of Antibodies for Exosome Detection

Fremont, CA, July 18, 2022: Biotium, a leading supplier and inventor of fluorescent cellular probes for life science research, announces the release of new ExoBrite™ Antibody Conjugates. These antibodies were curated specifically for optimal detection of exosome markers CD9, CD63, and CD81 in isolated exosomes or exosome extracts with little to no background. ExoBrite™ Antibody Conjugates are available in formulations for both flow cytometry and western blotting.

Extracellular vesicles (EVs), including exosomes, are increasingly studied for their roles in cell communication, and as potential targets for diagnostic and drug delivery applications. The most common proteins used as exosome markers are CD9, CD63, and CD81, members of the tetraspanin family. While antibodies targeting these proteins are available by commercial suppliers, few are validated or perform well for detection of EVs or exosomes. ExoBrite™ Flow Antibody Conjugates and ExoBrite™ Western Antibody Conjugates were developed by Biotium scientists for optimal detection of CD9, CD63, and CD81 exosome markers by flow cytometry and western blotting.

ExoBrite™ Flow Antibodies are designed for detection of isolated or bead-bound EVs by flow cytometry. The antibodies are available in 4 conjugates: ExoBrite™ 410/450 (Pacific Blue™ channel), ExoBrite™ 490/515 (FITC channel), ExoBrite™ 560/585 (PE channel with yellow laser), and ExoBrite™ R-PE (PE channel). Isotype controls are also available for each conjugate.